IMD101

IMD101 is a tumor microenvironment (TME)-activated wild-type (WT) interleukin-2 (IL-2) cytokine therapy. It is engineered by chemically conjugating WT IL-2 with a masking entity via a legumain-cleavable linker. This design ensures that IL-2 activity is inhibited in systemic circulation, thereby reducing the toxicity typically associated with high-dose IL-2 therapy, such as vascular leak syndrome. Upon reaching the TME, the mask is cleaved by legumain, a protease overexpressed in many tumors, restoring the full immune-activating function of WT IL-2 to stimulate T-cell and NK-cell responses against the tumor. Developed by Affinity Biopharmaceutical (Shanghai Yingmaide Medical Technology), IMD101 is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors.

Other names

TME-activated WT IL-2